Encapsulation of trans-dehydrocrotonin in liposomes: An enhancement of the antitumor activity

Journal of Biomedical Nanotechnology

Volumn 9, Issue 3, 2013, Pages 499-510

  Lapenda, T L S ^a   Morais, W A ^a   Almeida, F J F ^a   Ferraz, M S ^a   Lira, M C B ^a   Santos, N P S ^a   MacIel, M A M ^b   Santos Magalhaes N S ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Antitumor Activity; Cyclodextrin; Kinetics; Liposomes; Trans Dehydrocrotonin

Indexed keywords

ANTI-TUMOR ACTIVITIES; ENCAPSULATION EFFICIENCY; INCLUSION COMPLEX; KINETIC PROFILES; LIPOSOMAL FORMULATION; PHOSPHOLIPID BILAYER; TRANS-DEHYDROCROTONIN; TUMOR INHIBITION;

ANIMALS; CYCLODEXTRINS; DIALYSIS; DRUG PRODUCTS; DRUG THERAPY; ENCAPSULATION; ENZYME KINETICS; KINETICS; PHOSPHOLIPIDS; TUMORS;

LIPOSOMES;

ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; HYDROPROPYL BETA CYCLODEXTRIN; LIPOSOME; PHOSPHOLIPID; TRANS DEHYDROCROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; THROMBOCYTE COUNT;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; DITERPENES, CLERODANE; KINETICS; LIPOSOMES; LIVER; MALE; MICE; PARTICLE SIZE; REGRESSION ANALYSIS; SARCOMA; STATIC ELECTRICITY;

EID: 84876570534     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1554     Document Type: Article

References (41)

1. M. A. M. Maciel, A. C. Pinto, A. C. Arruda, S. G. S. R. Pamplona, F. A. Vanderlinde, A. J. Lapa, A. Echevarria, N. F. Grynberg, I. M. S. Cólus, R. A. F. Farias, A. M. L. Costa, and V. S. N. Rao, Ethnopharmacology, phytochemistry and pharmacology: a successful combination in the study of Croton cajucara. J. Ethnopharmacol. 70, 41 (2000).
2. N. F. Grynberg, A. Echevarria, J. E. Lima, S. S. R. Pamplona, A. C. Pinto, and M. A. M. Maciel, Anti-tumor activity of two 19-nor-clerodane diterpenes, trans-dehydrocrotonin and transcrotonin, from Croton cajucara. Planta Med. 65, 687 (1999).
3. P. S. Melo, G. Z. Justo, N. Durán, and M. Haun, Natural killer cell activity and anti-tumour effects of dehydrocrotonin and its synthetic derivatives. Eur. J. Pharmacol. 487, 47 (2004).
4. R. M. Silva, F. A. Santos, V. S. N. Rao, M. A. M. Maciel, and A. C. Pinto, Blood glucose- and triglyceride-lowering effect of transdehydrocrotonin, a diterpene from Croton cajucara Benth in rats. Diab. Obes. Metab. 3, 452 (2001).
5. E. J. B. Bighetti, A. R. M. Souza-Brito, E. C. De Faria, and H. C. F. Oliveira, Chronic treatment with bark infusion from Croton cajucara lowers plasma triglyceride levels in genetic hyperlipidemic mice. Can. J. Physiol. Pharmacol. 82, 387 (2004).
6. R. M. Silva, F. A. Santos, V. S. N. Rao, M. A. M. Maciel, and A. C. Pinto, The lipid-lowering effect of trans-dehydrocrotonin, a clerodane diterpene from Croton cajucara Benth in mice fed on high-fat diet. J. Pharm. Pharmacol. 53, 535 (2001).
7. A. R. Agner, M. A. M. Maciel, A. C. Pinto, and I. M. S. Cólus, Antigenotoxicity of trans-dehydrocrotonin, a clerodane diterpene from Croton cajucara. Planta Med. 67, 815 (2001).
8. J. A. Rodríguez, C. A. Hiruma-Lima, and A. R. M. Souza-Brito, Antiulcer activity and subacute toxicity of trans-dehydrocrotonin from Croton cajucara. Hum. Exp. Toxicol. 23, 455 (2004).
9. J. C. T. Carvalho, M. F. C. Silva, M. A. M. Maciel, A. C. Pinto, D. S. Nunes, R. M. Lima, J. K. Bastos, and S. J. Sarti, Investigation of anti-inflammatory and antinociceptive activities of transdehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara, Part 1. Planta Med. 62, 402 (1996).
10. A. M. Luna-Costa, J. C. R. Sila, A. R. Campos, V. S. N. Rao, M. A. M. Maciel, and A. C. Pinto, Antioestrogenic effect of transdehydrocrotonin, a nor-clerodane diterpene from Croton cajucara Benth in rats. Phytother. Res. 13, 689 (1999).
11. R. M. Silva, F. A. Oliveira, K. M. A. Cunha, J. L. Maia, M. A. M. Maciel, A. C. Pinto, N. R. F. Nascimento, F. A. Santos, and V. S. N. Rao, Cardiovascular effects of trans-dehydrocrotonin, a diterpene from Croton cajucara in rats. Vascul. Pharmacol. 43, 11 (2005).
12. M. C. Anazetti, P. S. Melo, N. Durán, and M. Haun, Comparative cytotoxicity of dimethylamide-crotonin in the promyelocytic leukemia cell line (HL60) and human peripheral blood mononuclear cells. Toxicol. 188, 261 (2003).
13. M. C. Anazetti, P. S. Melo, N. Durán, and M. Haun, Dehydrocrotonin and its derivative dimethylamide-crotonin induce apoptosis with lipid peroxidation and activation of caspases-2, -6 and -9 in human leukemic cells HL60. Toxicol. 203, 123 (2004).
14. D. H. A. Corrêa, P. S. Melo, C. A. A. De Carvallho, M. B. M. De Azevedo, N. Durán, and M. Haun, Dehydrocrotonin and its betacyclodextrin complex: Cytotoxicity in V79 fibroblasts and rat cultured hepatocytes. Eur. J. Pharmacol. 510, 17 (2005).
15. A. C. G. Freire, C. F. De Assis, A. O. Frick, P. S. Melo, M. Haun, H. Aoyama, N. Durán, M. M. Sauer, E. G. Kállas, and C. V. Ferreira, Influence of protein phosphatase inhibitors on HL60 cells death induction by dehydrocrotonin. Leukemia Res. 27, 823 (2003).
16. P. S. Melo, N. Duran, and M. Haun, Cytotoxicity of derivatives from dehydrocrotonin on V79 cells and Escherichia coli. Toxicology 159, 135 (2001).
17. J. A. Rodríguez and M. Haun, Cytotoxicity of trans-dehydrocrotonin from Croton cajucara on V79 Cells and rat hepatocytes. Planta Med. 65, 522 (1999).
18. E. Ojewole, I. Mackraj, P. Naidoo, and T. Govender, Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm. 70, 697 (2008).
19. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carrier. Nature Rev. Drug Disc. 4, 145 (2005).
20. K. A. Edwards and A. J. Baeumner, Liposomes in analyses. Talanta 68, 1432 (2006).
21. C. Mamot, D. C. Drummond, K. Hong, D. B. Kirpotin, and J. W. Park, Liposome-based approaches to overcome anticancer drug resistance. Drug Res. Update 6, 271 (2003).
22. M. E. Brewster and T. Loftsson, Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Del. Rev. 59, 645 (2007).
23. G. Piel, M. Piette, V. Barillaro, D. Castagne, B. Evrard, and L. Delattre, Betamethasone-in-cyclodextrin-in-liposome: The effect of cyclodextrins on encapsulation efficiency and release kinetics. Int. J. Pharm. 312, 75 (2006).
24. P. Hatzi, S. Mourtas, P. G. Klepetsanis, and S. G. Antimisiaris, Integrity of liposomes in presence of cyclodextrins: Effect of liposome type and lipid composition. Int. J. Pharm. 333, 167 (2007).
25. M. C. B. Lira, M. S. Ferraz, D. G. V. C. Da Silva, M. E. Cortes, K. I. Teixeira, N. P. Caetano, R. D. Sinisterra, G. Ponchel, and N. S. Santos-Magalhães, Inclusion complex of usnic acid with β-cyclodextrin: Characterization and nanoencapsulation into liposomes. J. Incl. Phenom. Macrocycl. Chem. 64, 215 (2009).
26. M. A. M. Maciel, A. C. Pinto, S. N. Brabo, and M. N. Da Silva, Terpenoids from Croton Cajucara. Phytochem. 49, 823 (1998).
27. M. A. M. Maciel, R. S. Leal, T. N. C. Dantas, and V. F. Veiga, Jr, Aspect of natural products on the discovery of new antitumoral and antimutagenic agents. Rev. Fitos 3, 37 (2007).
28. M. A. M. Maciel, A. C. Pinto, and C. R. Kaiser, NMR and structure review of some natural fluroclerodanes. Magn. Reson. Chem. 41, 278 (2003).
29. T. L. S. Lapenda, W. A. Morais, M. C. B. Lira, M. A. M. Maciel, N. S. Santos-Magalhães, Validation of a UV spectrophotometric method for determining trans-dehydrocrotonin in inclusion complexes with hydroxypropyl-β-cyclodextrin. Lat. Am. J. Pharm. 31, 97 (2012).
30. N. S. Santos-Magalhães, A. Pontes, V. M. W. Pereira, and M. N. P. Caetano, Colloidal carriers for benzantine penicillin G: nanoemulsions and nanocapsules. Int. J. Pharm. 208, 71 (2000).
31. D. Klose, F. Siepmann, K. Elkharraz, and J. Siepmann, PLGA-based drug delivery systems: Importance of the type of drug and device geometry. Int. J. Pharm. 354, 95 (2008).
32. J. Siepmann and F. Siepmann, Mathematical modeling of drug delivery. Int. J. Pharm. 364, 328 (2008).
33. N. P. S. Santos, S. C. Nascimento, M. S. O. Wanderley, N. T. Pontes- Filho, J. F. Da Silva, C. M. M. B. De Castro, E. C. Pereira, N. H. Da Silva, N. K. Honda, and N. S. Santos-Magalhães, Nanoencapsulation of usnic acid: An attempt to improve antitumour activity and reduce hepatotoxicity. Eur. J. Pharm. Biopharm. 64, 154 (2006).
34. D. Christensen, C. Foged, I. Rosenkrands, H. M. Nielsen, P. Andersen, and E. M. Agger, Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim. Biophys. Acta 1768, 2120 (2007).
35. A. R. Mohammed, V. W. Bramwell, A. G. A. Coombes, and Y. Perrie, Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 40, 30 (2006).
36. W. Abdelwahed, G. Degobert, S. Stainmesse, and H. Fessi, Freezedrying of nanoparticles: Formulation, process and storage considerations. Adv. Drug Deliv. 58, 1688 (2006).
37. J. Y. Kim, J. K. Kim, J. S. Park, Y. Byun, and C. K. Kim, The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 30, 5751 (2009).
38. P. Calvo, J. L. Vila-Jato, and M. J. Alonso, Evaluation of cationic polymer-coated nanocapsules as ocular drug carries. J. Pharm. Sci. 85, 530 (1996).
39. W. A. Morais, M. Costa, A. D. O. Paixão, M. A. M. Maciel, and N. S. Santos-Magalhães, Encapsulation and release characteristics of DCTN/PLGA microspheres. J. Microencapsul. 1, 1464 (2008).
40. T. Loftsson and M. E. Brewster, Pharmaceutical application of cyclodextrins. 1. Drug solubilization and stability. J. Pharm. Sci. 85, 1017 (1996).
41. M. Pallardy, M. Perrin-Wolff, and A. Biola, Cellular stress and apoptosis. Toxicol. In Vitro 11, 573 (1997).